351 related articles for article (PubMed ID: 2549204)
1. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer.
Slevin ML; Clark PI; Joel SP; Malik S; Osborne RJ; Gregory WM; Lowe DG; Reznek RH; Wrigley PF
J Clin Oncol; 1989 Sep; 7(9):1333-40. PubMed ID: 2549204
[TBL] [Abstract][Full Text] [Related]
2. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study.
Goodman GE; Crowley JJ; Blasko JC; Livingston RB; Beck TM; Demattia MD; Bukowski RM
J Clin Oncol; 1990 Jan; 8(1):39-47. PubMed ID: 2153194
[TBL] [Abstract][Full Text] [Related]
3. Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung: a randomized trial of the Bristol Lung Cancer Study Group.
Hong WK; Nicaise C; Lawson R; Maroun JA; Comis R; Speer J; Luedke D; Hurtubise M; Lanzotti V; Goodlow J
J Clin Oncol; 1989 Apr; 7(4):450-6. PubMed ID: 2538577
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial.
Wolf M; Havemann K; Holle R; Gropp C; Drings P; Hans K; Schroeder M; Heim M; Dommes M; Mende S
J Clin Oncol; 1987 Dec; 5(12):1880-9. PubMed ID: 2824710
[TBL] [Abstract][Full Text] [Related]
5. A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity.
Clark PI; Slevin ML; Joel SP; Osborne RJ; Talbot DI; Johnson PW; Reznek R; Masud T; Gregory W; Wrigley PF
J Clin Oncol; 1994 Jul; 12(7):1427-35. PubMed ID: 8021734
[TBL] [Abstract][Full Text] [Related]
6. Pilot study of cyclophosphamide-doxorubicin-vincristine-cisplatin-etoposide hybrid chemotherapy in small cell lung cancer.
Ohnoshi T; Hiraki S; Ueoka H; Kiura K; Kamei H; Horiguchi T; Kodani T; Maeda T; Tabata M; Shibayama T
Cancer; 1993 Sep; 72(5):1597-601. PubMed ID: 8394202
[TBL] [Abstract][Full Text] [Related]
7. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B.
Miller AA; Herndon JE; Hollis DR; Ellerton J; Langleben A; Richards F; Green MR
J Clin Oncol; 1995 Aug; 13(8):1871-9. PubMed ID: 7636529
[TBL] [Abstract][Full Text] [Related]
8. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses.
Tummarello D; Mari D; Graziano F; Isidori P; Cetto G; Pasini F; Santo A; Cellerino R
Cancer; 1997 Dec; 80(12):2222-9. PubMed ID: 9404698
[TBL] [Abstract][Full Text] [Related]
9. Sequencing and schedule effects of cisplatin plus etoposide in small-cell lung cancer: results of a North Central Cancer Treatment Group randomized clinical trial.
Maksymiuk AW; Jett JR; Earle JD; Su JQ; Diegert FA; Mailliard JA; Kardinal CG; Krook JE; Veeder MH; Wiesenfeld M
J Clin Oncol; 1994 Jan; 12(1):70-6. PubMed ID: 8270988
[TBL] [Abstract][Full Text] [Related]
10. Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy.
Souhami RL; Spiro SG; Rudd RM; Ruiz de Elvira MC; James LE; Gower NH; Lamont A; Harper PG
J Natl Cancer Inst; 1997 Apr; 89(8):577-80. PubMed ID: 9106647
[TBL] [Abstract][Full Text] [Related]
11. Interdigitating versus concurrent chemotherapy and radiotherapy for limited small cell lung cancer.
Komaki R; Shin DM; Glisson BS; Fossella FV; Murphy WK; Garden AS; Oswald MJ; Hong WK; Roth JA; Peters LJ
Int J Radiat Oncol Biol Phys; 1995 Feb; 31(4):807-11. PubMed ID: 7860392
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel in lung cancer: 1-hour infusions given alone or in combination chemotherapy.
Hainsworth JD; Greco FA
Semin Oncol; 1995 Dec; 22(6 Suppl 15):45-9. PubMed ID: 8643970
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up.
Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Hatlevoll R; Dahle R; Boye N; Wang M; Vigander T; Vilsvik J; Skovlund E; Hannisdal E; Aamdal S;
J Clin Oncol; 2002 Dec; 20(24):4665-72. PubMed ID: 12488411
[TBL] [Abstract][Full Text] [Related]
14. Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine.
Johnson BE; Bridges JD; Sobczeck M; Gray J; Linnoila RI; Gazdar AF; Hankins L; Steinberg SM; Edison M; Frame JN; Pass H; Nesbitt J; Holden D; Mulshine JL; Glatstein E; Ihde DC
J Clin Oncol; 1996 Mar; 14(3):806-13. PubMed ID: 8622028
[TBL] [Abstract][Full Text] [Related]
15. Small cell lung cancer (SCLC): a randomized trial of cyclophosphamide, adriamycin, vincristine plus etoposide (CAV-E) or teniposide (CAV-T) as induction treatment, followed in complete responders by alpha-interferon or no treatment, as maintenance therapy.
Tummarello D; Graziano F; Mari D; Cetto G; Pasini F; Antonio S; Isidori P; Gasparini S
Anticancer Res; 1994; 14(5B):2221-7. PubMed ID: 7840527
[TBL] [Abstract][Full Text] [Related]
16. Addition of etoposide to cyclophosphamide, doxorubicin, and vincristine for remission induction and survival in patients with small cell lung cancer.
Messeih AA; Schweitzer JM; Lipton A; Harvey HA; Simmonds MA; Stryker JA; Ricci JA; Hoffman SL; Gottleib RJ; Dixon RH
Cancer Treat Rep; 1987 Jan; 71(1):61-6. PubMed ID: 3024828
[TBL] [Abstract][Full Text] [Related]
17. Experience of a German multicenter study group with ifosfamide in small cell lung cancer.
Havemann K; Wolf M; Drings P; Hans K; Schroeder M; Holle R; Flechtner H; Goerg R; Becker H
Semin Oncol; 1989 Feb; 16(1 Suppl 3):9-18. PubMed ID: 2539648
[TBL] [Abstract][Full Text] [Related]
18. Combination chemotherapy with or without thoracic radiotherapy in limited-stage small-cell lung cancer: a randomized trial of the Southeastern Cancer Study Group.
Johnson DH; Bass D; Einhorn LH; Crawford J; Perez CA; Bartolucci A; Omura GA; Greco FA
J Clin Oncol; 1993 Jul; 11(7):1223-9. PubMed ID: 8391064
[TBL] [Abstract][Full Text] [Related]
19. Multimodal therapy for limited small-cell lung cancer: a randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders; and with wide-field versus reduced-field radiation in partial responders: a Southwest Oncology Group Study.
Kies MS; Mira JG; Crowley JJ; Chen TT; Pazdur R; Grozea PN; Rivkin SE; Coltman CA; Ward JH; Livingston RB
J Clin Oncol; 1987 Apr; 5(4):592-600. PubMed ID: 3031226
[TBL] [Abstract][Full Text] [Related]
20. Vincristine, doxorubicin and cyclophosphamide with and without etoposide in limited small cell lung cancer.
Nikkanen V; Liippo K; Ojala A; Jakobsson M; Järvinen M; Paloheimo S; Nordman E
Acta Oncol; 1990; 29(4):421-4. PubMed ID: 2167702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]